ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In the gynecologic expansion cohort of the first-in-human, phase 1 MYTHIC trial, the combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR inhibitor) produced durable objective responses in heavily…
Eflornithine (Iwilfin), an oral drug that blocks an enzyme cancer cells use to make polyamines needed for growth, is the first FDA-approved therapy specifically intended to reduce relapse risk in…
In the randomized, phase 3 PANOVA-3 trial, adding Tumor Treating Fields (TTFields) -- a wearable device that emits alternating electric fields through skin-worn arrays -- to standard chemotherapy significantly extended…
In the dose-optimization portion of the now-terminated phase 2/3 REFRaME-O1 trial, the antibody-drug conjugate luveltamab tazevibulin produced objective responses in patients with platinum-resistant ovarian cancer expressing folate receptor alpha, at…
In the single-arm, phase 1/2 EPCORE NHL-1 trial, epcoritamab — a subcutaneously-injected bispecific antibody that physically brings a patient's own T-cells into contact with lymphoma cells — produced an objective…
In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients…
An investigational alpha-lactalbumin-targeted vaccine, developed by Anixa Biosciences with Cleveland Clinic, was reported to be safe and to induce a protocol-defined immune response in 74% of participants across all three…
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…